Company / R&D Expense
AGIOS PHARMACEUTICALS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$339.5M
FY2025
5-year range
$220.8M / $339.5M
FY2021-FY2025
Trend
+12.7%
vs FY2024
Sector context
#51 of 210
Health Care
What the data says
AGIOS PHARMACEUTICALS, INC.'s r&d expense of $340M is higher than 76% of companies in the Health Care sector (FY2025). R&D Expense has increased for 3 consecutive years, from $221M in FY2022 to $340M in FY2025.
Based on SEC 10-K filings.
$340M in FY2025 with a 5-year CAGR of -0.1%. Top quartile in the Health Care sector.
Improved from $296M to $340M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 210This company $339.5M Sector average $644.0M
▼
-47.3% below sector average
Key checks
Key Insights
- AGIOS PHARMACEUTICALS, INC.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of -0.1%, indicating a declining trend.
- In FY2025, r&d expense increased 12.7% year-over-year.
- Ranks #51 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $339.5M | +12.7% |
| FY2024 | $301.3M | +1.9% |
| FY2023 | $295.5M | +33.8% |
| FY2022 | $220.8M | -14.1% |
| FY2021 | $257.0M | -24.7% |
| FY2020 | $341.3M | +59.3% |
| FY2019 | $214.3M | -2.7% |
| FY2018 | $220.2M | -24.8% |
| FY2017 | $292.7M | +32.9% |
| FY2016 | $220.2M | +304.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026